Acute Angle-Closure Glaucoma and Paroxetine
J Clin Psychiatry 1997;58(3):123-124 [letter]
© Copyright 2015 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Letter to the Editor
Sir: Acute angle-closure glaucoma has been linked to use of
tricyclic antidepressants and monoamine oxidase inhibitors.
Susceptible patients are described as those with a history of
angle-closure, age greater than 40 years, dilated pupils at initial
examination, a personal or family history of glaucoma, and a
history of ocular symptoms (visual abnormalities and/or eye
pain). While there is some debate about the role of antidepressant
medication in exacerbating or causing glaucoma, clinicians
have advocated use of serotonin selective reuptake inhibitors (SSRIs) in treatment of high-risk patients. We report a case of
acute angle-closure glaucoma related to paroxetine use in a patient
with mydriasis on examination prior to treatment but who
had no personal or family history of glaucoma.